论文信息 - Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. - 字舞流文

Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.

A. Enk | N. Halama | L. Umansky | D. Jaeger | C. Falk | J. Hassel | P. Beckhove | I. Karapanagiotou-Schenkel | N. Lang | J. Dick | S. Juenger | M. Bucur | I. Zoernig | G. Haag | L. Podola | C. Ziegelmeier | A. Freitag | J. Funk